Different neurotherapeutic actions of the weak cathepsin B inhibitors N-carbobenzyloxy-L-phenylalanylLalanyldiazomethylketone (PADK) and 2S,3S-trans-epoxysuccinyl-L-leucylamido-3-methylbutane ethyl ester (E64d; aloxistatin) may be due to their dissimilar potencies for blocking the calcium-activated protease calpain that has been linked to both Alzheimer’s disease and traumatic brain injury

H. Romine; M. C.  Pait; K. M.  Rentschler; Kaitlan Smith; A. Edwards; C. Colvin; B Sifford; Y. Abumohsen; R. Masters; D. Butler; B. A.  Bahr

Different neurotherapeutic actions of the weak cathepsin B inhibitors N-carbobenzyloxy-L-phenylalanylLalanyldiazomethylketone (PADK) and 2S,3S-trans-epoxysuccinyl-L-leucylamido-3-methylbutane ethyl ester (E64d; aloxistatin) may be due to their dissimilar potencies for blocking the calcium-activated protease calpain that has been linked to both Alzheimer’s disease and traumatic brain injury

H. Romine
, M. C. Pait
, K. M. Rentschler
, Kaitlan Smith
, A. Edwards
, C. Colvin
, B Sifford
, Y. Abumohsen
, R. Masters
, D. Butler
, B. A. Bahr

Jerry M. Wallace School of Osteopathic Medicine

Research output: Contribution to conference › Poster › peer-review

Original language	American English
State	Published - Nov 2017

Cite this

Romine, H., Pait, M. C., Rentschler, K. M., Smith, K., Edwards, A., Colvin, C., Sifford, B., Abumohsen, Y., Masters, R., Butler, D., & Bahr, B. A. (2017). Different neurotherapeutic actions of the weak cathepsin B inhibitors N-carbobenzyloxy-L-phenylalanylLalanyldiazomethylketone (PADK) and 2S,3S-trans-epoxysuccinyl-L-leucylamido-3-methylbutane ethyl ester (E64d; aloxistatin) may be due to their dissimilar potencies for blocking the calcium-activated protease calpain that has been linked to both Alzheimer’s disease and traumatic brain injury.

Different neurotherapeutic actions of the weak cathepsin B inhibitors N-carbobenzyloxy-L-phenylalanylLalanyldiazomethylketone (PADK) and 2S,3S-trans-epoxysuccinyl-L-leucylamido-3-methylbutane ethyl ester (E64d; aloxistatin) may be due to their dissimilar potencies for blocking the calcium-activated protease calpain that has been linked to both Alzheimer’s disease and traumatic brain injury. / Romine, H.; Pait, M. C. ; Rentschler, K. M. et al.
2017.

Research output: Contribution to conference › Poster › peer-review

Romine, H, Pait, MC, Rentschler, KM, Smith, K, Edwards, A, Colvin, C, Sifford, B, Abumohsen, Y, Masters, R, Butler, D & Bahr, BA 2017, 'Different neurotherapeutic actions of the weak cathepsin B inhibitors N-carbobenzyloxy-L-phenylalanylLalanyldiazomethylketone (PADK) and 2S,3S-trans-epoxysuccinyl-L-leucylamido-3-methylbutane ethyl ester (E64d; aloxistatin) may be due to their dissimilar potencies for blocking the calcium-activated protease calpain that has been linked to both Alzheimer’s disease and traumatic brain injury'.

Romine H, Pait MC, Rentschler KM, Smith K, Edwards A, Colvin C et al.. Different neurotherapeutic actions of the weak cathepsin B inhibitors N-carbobenzyloxy-L-phenylalanylLalanyldiazomethylketone (PADK) and 2S,3S-trans-epoxysuccinyl-L-leucylamido-3-methylbutane ethyl ester (E64d; aloxistatin) may be due to their dissimilar potencies for blocking the calcium-activated protease calpain that has been linked to both Alzheimer’s disease and traumatic brain injury. 2017.

Romine, H. ; Pait, M. C. ; Rentschler, K. M. et al. / Different neurotherapeutic actions of the weak cathepsin B inhibitors N-carbobenzyloxy-L-phenylalanylLalanyldiazomethylketone (PADK) and 2S,3S-trans-epoxysuccinyl-L-leucylamido-3-methylbutane ethyl ester (E64d; aloxistatin) may be due to their dissimilar potencies for blocking the calcium-activated protease calpain that has been linked to both Alzheimer’s disease and traumatic brain injury.

@conference{d0bdcd0367ac4ba1835ffea04847f2d1,

title = "Different neurotherapeutic actions of the weak cathepsin B inhibitors N-carbobenzyloxy-L-phenylalanylLalanyldiazomethylketone (PADK) and 2S,3S-trans-epoxysuccinyl-L-leucylamido-3-methylbutane ethyl ester (E64d; aloxistatin) may be due to their dissimilar potencies for blocking the calcium-activated protease calpain that has been linked to both Alzheimer{\textquoteright}s disease and traumatic brain injury",

author = "H. Romine and Pait, \{M. C.\} and Rentschler, \{K. M.\} and Kaitlan Smith and A. Edwards and C. Colvin and B Sifford and Y. Abumohsen and R. Masters and D. Butler and Bahr, \{B. A.\}",

year = "2017",

month = nov,

language = "American English",

}

TY - CONF

T1 - Different neurotherapeutic actions of the weak cathepsin B inhibitors N-carbobenzyloxy-L-phenylalanylLalanyldiazomethylketone (PADK) and 2S,3S-trans-epoxysuccinyl-L-leucylamido-3-methylbutane ethyl ester (E64d; aloxistatin) may be due to their dissimilar potencies for blocking the calcium-activated protease calpain that has been linked to both Alzheimer’s disease and traumatic brain injury

AU - Romine, H.

AU - Pait, M. C.

AU - Rentschler, K. M.

AU - Smith, Kaitlan

AU - Edwards, A.

AU - Colvin, C.

AU - Sifford, B

AU - Abumohsen, Y.

AU - Masters, R.

AU - Butler, D.

AU - Bahr, B. A.

PY - 2017/11

Y1 - 2017/11

M3 - Poster

ER -